Clinical trial · Observational
CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Early diagnosis of cancer allows for better treatment outcomes, higher survival rates, and lower costs of care. It is shown that cancer monitoring for cancer in at-risk populations is a key component in early diagnosis. The HMH Hennessey Institute for Cancer prevention and Applied Molecular Science (HICAP) is a newly founded institute, providing clinical services for cancer screening and risk assessment to the community, as well as research in cancer risk and prevention. The CanScan registry will prospectively collect data from participants in the form of questionnaires. The registry will also capture data that is collected as per non-research assessments, for participants who consent to participate. The registry will facilitate better understanding of cancer risk, screening, and diagnostics.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Risk | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Rate of Pathogenic Germline Variants (PGV)
- timeFrame
- 10 years from study initiation as defined based on the date the first patient was enrolled.
- description
- Compare the number of detected PGVs as measured by a universal multi-gene panel, proactively, in a diverse community-based population of individuals. PGV rate will be compared to NCCN genetic testing criteria at baseline, and to longitudinal cancer outcomes.
Secondary outcomes (4)
- measure
- Incidence of Cancer
- timeFrame
- 10 years from study enrollment.
- description
- The number of new cancer cases diagnosed in participants with specific PGV's (i.e. "at high risk" to develop cancer) compared to those without these markers (i.e. "low / average risk") over a period of ten years as described below.
- measure
- Genetic Risk Score (GRS)
- timeFrame
- 10 years from study enrollment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
* Adults ( 18 and older) * Ability to provide own consent * Must meet at least one of the below criteria, Indicating an increased risk for cancer, any of the following: * Family or personal history suggests a familial/hereditary disorder known or suspected of predisposition to cancer. * Personal factors associated with an increased risk for cancer include benign breast disease, polyps, tobacco use, etc.as defined by the investigator. * Family members of participating individuals. * Any participant in the HICAP program regardless of cancer risk
References
Publications (0)
Data not yet available